Inhibitor Therapeutics (OTCMKTS:INTI) Announces Quarterly Earnings Results

Inhibitor Therapeutics (OTCMKTS:INTI) released its quarterly earnings results on Wednesday. The company reported ($0.01) EPS for the quarter, Zacks reports.

Inhibitor Therapeutics Stock Performance

Shares of INTI traded up $0.01 during mid-day trading on Friday, reaching $0.10. 7,500 shares of the company were exchanged, compared to its average volume of 40,522. The business has a 50 day simple moving average of $0.08 and a two-hundred day simple moving average of $0.06. The stock has a market capitalization of $16.79 million, a PE ratio of -9.73 and a beta of -0.46. Inhibitor Therapeutics has a 52 week low of $0.03 and a 52 week high of $0.12.

Inhibitor Therapeutics Company Profile

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc and changed its name to Inhibitor Therapeutics, Inc in August 2019.